OTTAWA, Aug. 13, 2018 /CNW/ - Health Canada is warning Canadians of the potential risk of cancer relapse in patients withcancer of the blood and lymph nodes who have undergone stem cell transplant and are taking long-term azithromycin (Zithromax).
The drug was being tested in clinical trials outside Canada with the goal of preventing
As a result, the U.S. Food and Drug Administration (FDA) issued a warning that azithromycin should not be given long-term to prevent a certain inflammatory lung condition in this specific patient population.
The Canadian label for azithromycin does not include an indication for use to prevent bronchiolitis obliterans syndrome following stem cell transplants. Azithromycin has been used for its approved indications for more than 20 years. Those approved indications are not affected by this warning.
Health Canada has not received any reports of Canadian cases of cancer relapse in stem cell transplant patients taking azithromycin. However, the Department will continue to monitor the issue and take appropriate action, if necessary. If any new safety concerns are identified, Health Canada will update Canadians, including health professionals, as required.
What you should do:
What healthcare professionals should do:
Report health or safety concerns To report a side effect to a health product to Health Canada:
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
Également disponible en français
SOURCE Health Canada
Subscribe to our Free Newsletters!